our progress
|
Over the last decade, EBRP has made remarkable strides, including helping to accelerate the first three FDA-approved EB treatments in the past two years alone. Two of these treatments were directly funded by EBRP under our Venture Philanthropy model.
|
|
"Modeling and Targeting RDEB with Human Skin Organoids-on-Chip" "Developing Ex-vivo and In-vivo Base and Prime Editing Strategies to Treat Recessive Dystrophic Epidermolysis Bullosa" |
"Utilizing SRI-41315 Alone and in Combination with Gentamicin to Promote Readthrough in Patients with RDEB and JEB" "Nonsense readthrough using gentamicin or ELX-02 in combination with potentiator compounds for the treatment of Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa" |
"Validating New Anti-Cancer Targets for Dystrophic Epidermolysis Bullosa" "Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients" |
|
|
21 INSTITUTIONS, ONE FOCUS: CURING EB
Collaboration is central to our model. The EB Clinical Research Consortium (EBCRC) allows each research team to benefit from the others, accelerating progress to heal EB. |
DRIVING RESULTS FOR PATIENTS.
We find the most promising research projects to fund. But we don't just sign a check and hope for the best. Our innovative Venture Into Cures system ensures maximum impact for the EB community. |
MAKE A DONATION
Thanks to EBRP's pioneering Venture Philanthropy model, every donation has the potential to grow to multiples of its original value.
Donate today to fund the science that will find the cure.
Donate today to fund the science that will find the cure.
|
|